ArticleJournal of the National Cancer Institute2017
Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.
Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Exposure to per- and polyfluoroalkyl substances and breast cancer risk: a systematic review and meta-analysis of epidemiologic studies.American journal of epidemiology · 2024Pooled it
- Genetic and lifestyle factors for breast cancer risk assessment in Southeast China.Cancer medicine · 2023Trial
- A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease.Cancer prevention research (Philadelphia, Pa.) · 2018Trial
- Adiposity and risk of breast cancer in 280 000 Chinese women: a prospective cohort study.International journal of epidemiology · 2026Observational
- Interaction between the breast tumor microenvironment and gut microbiome.Gut microbes · 2025Review
- Lifestyle changes and postmenopausal breast cancer risk in women from the European Prospective Investigation into Cancer and Nutrition.Breast cancer research : BCR · 2025Article
- Cardiovascular Risk, Health Metrics, and Cancer Prediction: A Scoping Review.JACC. CardioOncology · 2025Article
- Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer.JAMA oncology · 2025Article
- Article
- Mammographic density and breast cancer risk among Black American women.International journal of cancer · 2025Article
- Association between serum urate levels, gout and breast cancer: observational and Mendelian randomization analyses.Translational cancer research · 2025Article
- Review
- Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Population Attributable Risk of Advanced-Stage Breast Cancer by Race and Ethnicity.JAMA oncology · 2024Article
- Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study.Breast cancer research and treatment · 2024Article
- Trajectories of body mass index in adulthood and risk of subtypes of postmenopausal breast cancer.Breast cancer research : BCR · 2023Article
- Risk of estrogen receptor-specific breast cancer by family history of estrogen receptor subtypes and other cancers.Journal of the National Cancer Institute · 2023Article
- The role of obesity and bariatric surgery-induced weight loss in breast cancer.Cancer metastasis reviews · 2022Review
- Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation.The Journal of clinical endocrinology and metabolism · 2022Article
- Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer.NPJ breast cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Background: Risk factors may differentially influence development of estrogen receptor (ER)-positive vs -negative breast cancer. We examined associations with strong, prevalent risk factors by ER subtype. Methods: Of 1 279 443 women age 35 to 74 years participating in the Breast Cancer Surveillance Consortium, 14 969 developed ER-positive and 3617 developed ER-negative invasive breast cancer. We calculated hazard ratios (HRs) using Cox regression and compared ER subtype hazard ratios at representative ages or by menopausal status using Wald tests. All statistical tests were two-sided. Results: For women age 40 years, compared with no prior biopsy, ER-positive vs ER-negative HRs were 1.53 (95% CI = 1.30 to 1.81) vs 1.26 (95% CI = 0.90 to 1.76) for nonproliferative disease, 1.63 (95% CI = 1.23 to 2.17) vs 1.41 (95% CI = 0.78 to 2.57) for proliferative disease without atypia, and 4.47 (95% CI = 2.88 to 6.96) vs 0.20 (95% CI = 0.02 to 2.51) for proliferative disease with atypia. Benign disease proliferation risk was stronger for ER-positive than ER-negative cancer for women age 35 years (Wald P = .04), age 40 years (Wald P = .04), and age 50 years (Wald P = .06). Among pre/perimenopausal women, body mass index (BMI) had a stronger association with ER-negative than ER-positive cancer (obese II/III vs. normal weight: HR = 1.52, 95% CI = 1.19 to 1.94; vs 1.21, 95% CI = 1.08 to 1.36). Increasing BMI similarly increased ER-positive and ER-negative cancer risk among postmenopausal hormone users (Wald P = .15) and nonusers (Wald P = .08). Associations with ER subtype varied by race/ethnicity across all ages (P < .001) and by family history of breast cancer and breast density for specific ages. Conclusions: Strength of risk factor associations differed by ER subtype. Separate risk models for ER subtypes may improve identification of women for targeted prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.